GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » Cyclically Adjusted Revenue per Share

Betta Pharmaceuticals Co (SZSE:300558) Cyclically Adjusted Revenue per Share : ¥4.72 (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Betta Pharmaceuticals Co's adjusted revenue per share for the three months ended in Mar. 2025 was ¥2.200. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥4.72 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-04-28), Betta Pharmaceuticals Co's current stock price is ¥51.16. Betta Pharmaceuticals Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ¥4.72. Betta Pharmaceuticals Co's Cyclically Adjusted PS Ratio of today is 10.84.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Betta Pharmaceuticals Co was 12.55. The lowest was 9.34. And the median was 11.26.


Betta Pharmaceuticals Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Betta Pharmaceuticals Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Betta Pharmaceuticals Co Cyclically Adjusted Revenue per Share Chart

Betta Pharmaceuticals Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 4.60

Betta Pharmaceuticals Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 4.61 4.60 4.72

Competitive Comparison of Betta Pharmaceuticals Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Betta Pharmaceuticals Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Betta Pharmaceuticals Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Betta Pharmaceuticals Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Betta Pharmaceuticals Co's Cyclically Adjusted PS Ratio falls into.


;
;

Betta Pharmaceuticals Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Betta Pharmaceuticals Co's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=2.2/115.1156*115.1156
=2.200

Current CPI (Mar. 2025) = 115.1156.

Betta Pharmaceuticals Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.000 97.624 0.000
201412 0.000 99.000 0.000
201512 0.548 100.600 0.627
201603 0.772 102.200 0.870
201606 0.670 101.400 0.761
201609 0.756 102.400 0.850
201612 0.643 102.600 0.721
201703 0.577 103.200 0.644
201706 0.657 103.100 0.734
201709 0.692 104.100 0.765
201712 0.623 104.500 0.686
201803 0.732 105.300 0.800
201806 0.750 104.900 0.823
201809 0.854 106.600 0.922
201812 0.759 106.500 0.820
201903 0.943 107.700 1.008
201906 0.977 107.700 1.044
201909 1.212 109.800 1.271
201912 0.725 111.200 0.751
202003 1.587 112.300 1.627
202006 0.736 110.400 0.767
202009 1.367 111.700 1.409
202012 0.879 111.500 0.908
202103 1.465 112.662 1.497
202106 1.287 111.769 1.326
202109 1.289 112.215 1.322
202112 1.222 113.108 1.244
202203 1.397 114.335 1.407
202206 1.650 114.558 1.658
202209 0.998 115.339 0.996
202212 1.667 115.116 1.667
202303 1.241 115.116 1.241
202306 1.866 114.558 1.875
202309 1.704 115.339 1.701
202312 0.971 114.781 0.974
202403 1.724 115.227 1.722
202406 1.899 114.781 1.905
202409 1.954 115.785 1.943
202412 1.315 114.893 1.318
202503 2.200 115.116 2.200

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Betta Pharmaceuticals Co  (SZSE:300558) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Betta Pharmaceuticals Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=51.16/4.72
=10.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Betta Pharmaceuticals Co was 12.55. The lowest was 9.34. And the median was 11.26.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Betta Pharmaceuticals Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Betta Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 355, Xingzhong Road, Economic and Technological Development Zone, Yuhang District, Zhejiang Province, Hangzhou, CHN, 311100
Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.
Executives
Wang Jia Bing Directors, executives
Ding Lie Ming Directors, executives
Cai Wan Yu Executives

Betta Pharmaceuticals Co Headlines

No Headlines